Eli Lilly’s $8 billion purchase of Loxo Oncology in January wasn’t supposed to be a tech-style acqui-hire. But it’s turning into one.

On Thursday, the drug giant announced that it is renaming its early cancer drug development arm Loxo Oncology at Lilly, and that the new unit will be helmed by Josh Bilenker, who had been Loxo’s CEO, along with his whole team from the biotech startup, including Jacob Van Naarden, who was the company’s chief operating officer, and Nisha Nanda, its chief development officer. The group is also hiring Dr. David Hyman, the Memorial Sloan Kettering oncologist who spearheaded the company’s early cancer trials, as chief medical officer.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy